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Abstract  
Bladder cancer is a frequently recurring disease with a very poor prognosis when 
progressed to invasive stages, and tumor–associated blood vessels play a crucial role 
in this process. In order to identify novel biomarkers associated with progression, we 
isolated blood vascular endothelial cells (BECs) from human invasive bladder cancers 
and matched normal bladder tissue, and found that tumor-associated BECs greatly 
upregulated the expression of insulin receptor (INSR). High expression of INSR on 
BECs of invasive bladder cancers was significantly associated with shorter 
progression-free and overall survival. Furthermore, increased expression of the INSR 
ligand IGF-2 in invasive bladder cancers was associated with reduced overall 
survival. INSR may therefore represent a novel biomarker to predict cancer 
progression. Mechanistically, we observed pronounced hypoxia in human bladder 
cancer tissue, and found a positive correlation between the expression of the hypoxia 
marker gene GLUT1 and vascular INSR expression, indicating that hypoxia drives 
INSR expression in tumor-associated blood vessels. In line with this, exposure of 
cultured BECs and human bladder cancer cell lines to hypoxia led to increased 
expression of INSR and IGF-2, respectively, and IGF-2 increased BEC migration 
through the activation of INSR in vitro. Taken together, we identified vascular INSR 
expression as a potential biomarker for progression in bladder cancer. Furthermore, 
our data suggest that IGF-2 / INSR mediated paracrine crosstalk between bladder 
cancer cells and endothelial cells which is functionally involved in tumor 
angiogenesis and my thus represent a new therapeutic target. 
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Introduction  
Bladder cancer ranks among the top five most commonly diagnosed cancers of 
males in North America [1] and occurs either as non-invasive (NIBC, pTa) or 
invasive bladder cancer (IBC, stages pT1-pT4 depending on the degree of 
invasiveness). NIBC have a good prognosis with 94% of patients surviving ≥5 years 
after tumor resection. However, 35% of them will experience cancer recurrence 
within the first year after surgery, requiring additional surgical interventions [2]. In 
contrast, the 5-year survival of patients with IBC is much lower: 68% for pT2 (muscle 
invasive), and <15% for pT3 and pT4 (invasion into perivesical tissue and to distant 
organs, respectively) [3], despite aggressive treatment including surgery (partial or 
complete cystectomy), radio- and chemotherapy [4]. The lack of suitable biomarkers 
that would allow to reliably predict patients likely to suffer from cancer recurrence 
and/or progression remains a major obstacle for a more efficient treatment of bladder 
cancer. 
We previously reported that the tumor-associated blood vasculature plays an 
important role in the progression of bladder cancer and identified endocan, a 
transcriptional target of the VEGF-A, as a marker of tumor vessels and a mediator of 
angiogenesis [5]. However, targeted therapy to block VEGF-A (e.g. using 
bevacizumab) or its cognate receptors has shown no or only little survival benefits in 
bladder cancer (BC [6,7]), suggesting that other pathways and mechanisms involved 
in vascular remodeling are more relevant in the context of this disease. Furthermore, it 
is currently unknown how the microenvironment in IBC contributes to tumor 
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invasiveness and metastasis, but it is conceivable that the highly angiogenic 
vasculature is directly or indirectly involved in these processes. Therefore, we aimed 
to identify additional vascular proteins or pathways which could serve as prognostic 
markers and/or targets for future therapy. Transcriptional profiling of tumor-
associated blood vascular endothelial cells (tBEC) from IBC compared to endothelial 
cells from adjacent normal bladder tissue (nBEC) revealed a strong upregulation of 
insulin receptor (INSR). Importantly, we found that vascular INSR expression levels 
closely correlated with survival parameters, suggesting it as a new biomarker for 
disease progression. Concomitantly, the INSR ligand IGF-2 was upregulated in the 
cancer tissue, suggesting that there is active crosstalk between cancer and endothelial 
cells via IGF-2/INSR signaling in IBC. In addition, we identified tissue hypoxia as the 
underlying mechanisms for the upregulation of INSR and IGF-2, and investigated the 
functional role of this pathway in angiogenesis and tumor progression both in vitro 
and in a mouse model of cancer. 
 
Materials and methods  
Tumor and normal tissue samples 
Clinically annotated frozen and paraffin embedded cancer and normal tissue 
samples were obtained from the University Hospital Zurich (USZ). Tissue collection 
was approved by the SPUK-GGU-USZ Ethics Committee (KEK-StV-Nr 02/09) and 
written informed consent was obtained from each patient.  
 
Laser-capture microdissection and transcriptional profiling of blood vessels 
from bladder tissue 
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Laser capture microdissection on frozen samples of IBC (5 patients; pT1-
pT4), RNA isolation, cDNA generation and microarray hybridization were performed 
as described [5]. The microarray data are available at GEO under accession number 
GSE41614.  
 
Immunohistochemistry on human paraffin embedded tissue samples 
Immunohistochemical stainings of paraffin-embedded tissue sections and the 
TMAs were performed as described [5], using a mouse monoclonal anti-human INSR 
antibody (4 μg/ml, clone CT-3, AHR0271, Invitrogen, USA), using a rabbit 
polyclonal anti-human GLUT1 antibody (1:1000, AB1341, Merck Millipore, USA), 
as well as biotin-labeled horse anti-mouse (5 μg/ml). Signals were detected with 
avidin–coupled peroxidase and 3-amino-9-ethylcarbazole (AEC) or 3,3-diamino-
benzidine (DAB). 
 
Endothelial cell migration assays 
The monolayer wound healing assay was performed as described [8]. See 
Supplementary materials and methods for details. 
 
Tumor mouse model 
Tie2-Cre and INSRfl/fl mice on the C57Bl6 background have been described 
previously [9-11] and were bred in house to generate Cre+INSRfl/fl mice lacking 
endothelial INSR expression and Cre-INSRfl/fl control littermates. MB49 BC line [12] 
was obtained from Dr. Angelica Loskog (University of Uppsala) and Dr. Martin 
Sommerauer (University of Luebeck). Luc2-expressing MB49 murine BC cells were 
cultured in DMEM (Life Technologies) with 10% FBS. Tumor cells (1x105) were 
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injected s.c, into the flank of female Cre+INSRfl/fl mice (N=13) or Cre-INSRfl/fl control 
littermates (N=11) mice (performed under inhalation anesthesia-2.5% isolfluorane). 
The smallest and largest tumor diameter were measured with a digital caliper 
every second day, and tumor volumes were calculated as: volume = π/6 x (smaller 
diameter2 x larger diameter). On day 14 after tumor implantation, animals were 
injected i.p. with the hypoxia marker pimonidazole hydrochloride (NPI) (60 mg/kg, 1 
h before sacrifice) and with luciferine (150 mg/kg, 10 min before sacrifice). Right 
after sacrifice, the primary tumor, inguinal and axillary lymph nodes, lungs and livers 
were dissected, and imaged using an IVIS system (Caliper). All experiments were 
performed in accordance with animal protocol 12/2015 approved by the Kantonales 
Veterinaeramt Zurich. 
 
Results  
High expression levels of insulin receptor on blood vessels of bladder cancers are 
associated with shorter progression-free and overall survival of patients.  
We previously performed a transcriptional analysis of bladder cancer-
associated blood endothelial cells (tBEC) compared to adjacent normal bladder 
endothelial cells (nBEC) using laser-capture microdissection (LCM) and microarray 
analysis [5]. The high purity of captured endothelial cell content was confirmed by 
high expression of PECAM1 (endothelial cell marker; among 15% highest expressed 
genes) and low expression of KRT7 (urothelial cell marker; among 10% lowest 
expressed genes). 
We noticed a highly significant upregulation (>4-fold upregulation, padj<0.01) 
of insulin receptor (INSR) in tBEC, and decided to investigate this phenomenon 
further, due to the potential effects of this important receptor on cell metabolism and 
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angiogenesis. RT-qPCR analysis confirmed that INSR mRNA expression was highly 
increased in 5 samples of tBECs compared to nBECs (Figure 1A), and the presence 
of INSR protein expression on tumor-associated vessels of BC specimen was 
validated by immunostaining (Figure 1B). Of note, immunohistochemical analysis 
revealed that INSR is upregulated in the vasculature of various other solid tumor 
types (Supplementary Figure 1). INSR expression was however undetectable on 
blood vessels in various healthy tissues, indicating that INSR is a general tumor 
vessel marker (Supplementary Figure 2). Semi-quantitative measurement of 
vascular INSR expression in 63 samples of IBC (Figure 1C, Supplementary Table 
S1) followed by Kaplan-Meier analysis revealed that the progression-free survival 
and the overall survival of patients with strong vascular INSR expression (n=12, 
Nevents=8 and n=12, Nevents=9, respectively) was much shorter than of those with no, or 
weak expression (n=51, Nevents=19, p=0.003, Figure 1D; n=51, Nevents=23, p=0.004, 
Figure 1E). We also analyzed INSR expression in 90 NIBC cases ([13], Figure 1F; 
Supplementary Table S2). The patients with strong vascular INSR expression 
(n=53, Nevents=31) had a tendency for shorter recurrence-free survival times than those 
with no or weak expression (n=37, Nevents=16, p=0.087; Figure 1G). In contrast, 
INSR staining in tumor cells was absent or very weak in all tumor samples we 
analyzed, indicating that tBECs are the strongest INSR-expressing cells within the BC 
microenvironment (Figure 1C, 1F). Using a publicly available TCGA dataset on 
invasive cancer [14], we observed that INSR was significantly upregulated in 
papillary-like Luminal Cluster I ((N (Cluster I)= 43; N (Cluster II)=50, p<0.01; N 
(Cluster III)=35, p<0.001; N (Cluster IV)=15, p<0.001; Supplementary Figure 3A). 
Interestingly, the same cluster showed significant upregulation of endocan, a 
molecule that we have previously identified to correlate with invasiveness of BC and 
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angiogenesis [5]. Moreover, the same cluster showed significant downregulation of 
the thromspondin-1 (TSP1). We have previously found that TSP1 is anti-angiogenic 
and has tumor-suppressing activity [15,16]. Besides, IBC pateints with low TSP1 
expression showed decreased overall survival and increased microvascular density 
[17].  Based on these findings, it is possible that the papillary-like Luminal Cluster I is 
particularly dependent on angiogenesis and could benefit from anti-angiogenic 
therapy. 
We also compared the expression of INSR in IBC of different histology from the 
TCGA database [14] and identified a significantly higher expression (p<0.001) in 
papillary (N=137) vs. non-papillary BC (N=285, Supplementary Figure 3B). BCs 
with lymphovascular invasion (N=88) had a significantly upregulated INSR 
expression (p<0.01, Supplementary Figure 3C) compared to tumors without signs of 
lymphovascular invasion (N=160). Moreover, BCs that metastasized (N=7) showed 
significantly increased levels of INSR (p<0.05, Supplementary Figure 3D) versus 
BCs without any evidence of metastasis (N=69). 
 
INSR expression by blood vascular endothelial cells is upregulated upon hypoxia  
Due to their high rate of proliferation and chaotic blood vessel network, the 
majority of cancers are hypoxic [18,19]. As we saw high expression of INSR on tBEC 
in majority of solid cancer, we therefore hypothesized that hypoxia might be 
responsible for endothelial INSR expression. Human umbilical vein endothelial cells 
(HUVECs) and human dermal blood vascular endothelial cells (BECs) were exposed 
to hypoxia for 24h, and the expression of INSR was analyzed by RT-qPCR. Hypoxia 
led to increased INSR expression (Figure 2A; 1.7-3.1-fold and 1.4-3.8-fold, 
respectively). On the other hand, among four BC cell lines tested, only the one 
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derived from high-grade cancer (T24; grade III) upregulated INSR expression upon 
hypoxia (1.4-2.2-fold; Figure 2B). This indicates that INSR expression is regulated 
by hypoxia specifically in endothelial cells. 
In order to test whether hypoxia might also be responsible for vascular INSR 
expression in human BC, we indirectly assessed the level of hypoxia in 63 IBC cases 
(same as in Figure 1C, Supplementary Table S1) by staining for the hypoxia-
responsive marker GLUT1 (SLC2A1; Figure 2C, [20,21]). Semi-quantitative scoring 
of GLUT1 expression revealed a clear trend for association between INSR and 
GLUT1 staining (GLUT1 low/INSR low=27, GLUT1 high/INSR low=24, GLUT1 
low/INSR high=3, GLUT1 high/INSR high=9 p=0.08, Figure 2D). Of note, 
significantly increased expression of GLUT1 was also detected in LCM-isolated 
blood vascular endothelial cells from 5 BCs (tBEC) compared to those from the 
adjacent normal bladder tissue (nBEC), suggesting that the tBECs themselves were 
also hypoxic to some extent (516.5–6897.0-fold; Figure 2E). Furthermore, GLUT1 
expression and INSR expression were significantly correlated in these samples 
(p=0.02, r=0.72, Figure 2F). In line with this, in addition to high intensity staining of 
GLUT1 in tumor cells, we could observe a weak GLUT1 staining in vessels in the 
vicinity of tumor cells. Furthermore, GLUT1 upregulation was also detectable in 
BECs exposed to hypoxia in vitro (4.4-6.0-fold; Supplementary Figure 4A).  
GLUT1 has been shown to be induced by the hypoxia-inducible factor 1A (HIF1A, 
[22]), a transcription factor that becomes transcriptionally active upon a decrease in 
tissue oxygen levels, and that induces the expression of several hypoxia response 
genes [23]. We therefore hypothesized that INSR is also under control of HIF1A in 
endothelial cells. Using publically available ChIP-Seq data from the ENCODE project 
(see Supplementary materials and methods for details), we assessed whether the 
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hypoxia-driven upregulation of INSR might be directly regulated by HIF1A. Whereas 
we found no evidence of HIF1A binding to the promoter, we observed a HIF1A 
binding peak around 100 kb downstream of the transcriptional start site (TSS) in an 
intronic region of the INSR gene which contained all the histone signatures 
(enrichment of H3K4me1 and H3K27ac) typical of an enhancer element (Figure 2F). 
Interestingly, the H3K27ac mark in this putative enhancer region was only observed 
under hypoxia. Typically, enhancer elements interact with the TSS of a gene to up-
regulate its expression. To investigate this link, we utilized ChIA-PET data [24], 
which map regions that are in close chromosomal proximity, and observed a clear 
interaction between the putative enhancer and the TSS of INSR (Figure 2F). Taken 
together, these findings suggest that the enhancer and its interaction with HIF1A and 
the TSS of INSR are important for the up-regulation of INSR transcription.  
 
Insulin receptor isoform-A is the major isoform expressed in tumor-associated 
endothelial cells and in endothelial cells in vitro. 
Two alternative splice isoforms of INSR have been described. The INSR-A 
isoform lacks exon 11 which encodes 12 amino acid residues at the C-terminus.  
INSR-A binds to IGF-2 with very high affinity, in contrast to INSR-B [25], that is 
expressed predominantly in insulin responsive tissues (liver, muscle, adipose tissue 
and kidney). 
In LCM isolated tBEC, the majority of the INSR transcript consisted of INSR-A 
(Figure 3A), while in LCM isolated endothelial cells from healthy bladder tissue 
expression of both isoforms was very low (at the limit of detection for RT-qPCR; data 
not shown). Similarly, in vitro cultured BECs and HUVECs showed a higher 
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expression of INSR-A compared to INSR-B (14.5–31.7-fold, BECs; 6.1–24.8-fold, 
HUVEC).  
 
IGF-2 is upregulated by hypoxia and higher levels of IGF-2 are associated with 
shorter overall survival of patients with IBC.  
We then investigated if hypoxia might also induce the expression of two 
physiological ligands of INSR, IGF-1 and IGF-2. When subjected to hypoxia, BECs 
expressed increased levels of IGF-2 (1.4-1.9-fold; Figure 4A) but not of IGF-1 (0.9-
1.1-fold; Supplementary Figure 4B). Cultured BC and urothelial cells reacted with 
an even more pronounced increase in IGF-2 expression (Figure 4B), while IGF-1 
expression was undetectable (data not shown). To test whether hypoxia observed in 
human BC was associated with increased IGF-2 expression as well, we analyzed 
several publicly available gene expression datasets of total BC and control bladder 
tissue [26-28]. Analysis of these 3 datasets revealed significantly higher IGF-2 
expression levels in IBC compared to normal bladder tissue (NB) and to normal 
bladder tissue that was adjacent to BC (NAB) (from [26]: 2.6-fold higher in IBC 
(n=85) than in NAB (n=45), Figure 4C; from [27]: 6.8-fold and 5.8-fold higher in 
IBC (n=13) than in NB (n=9) and NAB (n=5), respectively, Figure 4D; from [28]: 
2.8-fold and 2.5-fold higher in IBC (n=141) than in NB (n=10) and NAB (n=58), 
respectively, Figure 4E). Two of the datasets also included expression from NIBC, in 
which IGF-2 expression was also elevated (from [27]: 8.0-fold and 6.9-fold higher 
expression in NIBC (n=15) compared to NB (n=9) and NAB (n=5), respectively, 
Figure 4C; and from [28]: 1.8-fold and 1.6-fold higher expression in NIBC (n=24) 
compared to NB (n=10) and NAB (n=58), respectively, Figure 4D).  
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The large number of IBC samples and long clinical follow-up in one of the 
datasets [28] allowed us to compare overall-survival of patients with higher versus 
lower IGF-2 expression. Based on receiver operating characteristic analysis (ROC), 
patients were stratified into two groups of high (log2 expression>9.86 (n=73, 
Nevents=21)) and low IGF-2 expression (log2 expression<9.86 (n=68, Nevents=10)). 
Kaplan-Meier analysis revealed that the survival times of patients with high 
expression of IGF-2 tended to be shorter (p=0.096, Figure 4F) In addition, when we 
analyzed the dataset from the cancer genome atlas project (TCGA) for BC [14], again 
dividing patients into a high and low IGF-2 expression group by ROC analysis (log2 
expression > or < 6.9 (n=86, Nevents=31 and n=91, Nevents=24, respectively), high IGF-
2 expression was significantly associated with a shorter survival time (p<0.05, Figure 
4G). Taken together, these data suggest that hypoxia initiates crosstalk between IGF-2 
expressing BC cells and INSR expressing endothelial cells, which strongly correlates 
with a poor prognosis. 
 
IGF-2 activates endothelial migration though INSR independently of VEGFR-2 
Next, we sought to determine whether INSR stimulation is involved in cellular 
processes that contribute to angiogenesis. Using the endothelial scratch closure assay, 
we tested the effect of known agonists of INSR (Insulin, IGF-1, IGF-2) on endothelial 
migration. The strongest inducer of EC migration was IGF-2 (500 ng/ml, a 
concentration within the physiological range of 200-800 ng/ml [29]; 19.5-27.9% 
scratch closure above control, Figure 5A), followed by insulin (1 μM, 16.6-16.9%, 
Supplementary Figure S5A) and IGF-1 (500 ng/ml, 12.6-19.2%, Supplementary 
Figure S5B). IGF-2 used at 100 ng/ml induced cell migration almost efficiently as 
VEGF-A (20 ng/ml), the most powerful inducer of EC migration (11.0-23.1% relative 
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scratch closure above control, Figure 5B). The strong effect of IGF-2 compared to 
insulin or IGF-1 is in accordance with the predominant expression of INSR-A by 
cultured BECs and HUVECs noted earlier, which binds IGF-2 with high affinity. One 
of the ways that resistance to VEGF-A angiogenesis inhibitors arises is due to 
upregulation of other pro-angiogenesis factors [30,31]. Interestingly, we found that 
the migration-stimulatory effect of IGF-2 on cultured endothelial cells was 
independent of VEGFR-2 (Figure 5B). To confirm that the prominent activity of 
IGF-2 on endothelial was indeed mediated by INSR, we used an INSR-specific 
blocking antibody (IR Ab, [32]), an inhibitor of IGF-1R activation, picropodophyllin 
(PPP), and an inhibitor of both, INSR and IGF-1R activation, GSK1838705. IR Ab 
used at 10 nM completely blocked the IGF-2-induced migration (Figure 5C), PPP (50 
nM) only partially inhibited the IGF-2-induced migration (Figure 5D) and 
GSK1838705 (100 nM) completely blocked the migration of IGF-2 (Figure 5E). 
Futhermore, we found that IR Ab (10 nM) blocked the effect of insulin 
(Supplementary Figure S5C) but not of IGF-1 (Supplementary Figure S5D) while 
PPP (50 nM) successfully blocked IGF-1 action (Supplementary Figure S5E). 
GSK1838705 (100 nM) blocked successfully the action of insulin and IGF-1 
(Supplementary Figure S5F-G), as expected. Thus, BEC migration induced by 
insulin and IGF-2 appears to involve the INSR, whereas the effect of IGF-1 is only 
mediated by the IGF-1R. On the other hand, proliferation of BECs and HUVECs 
under normoxic and hypoxic conditions was hardly affected by treatment with insulin, 
IGF-1 or IGF-2 (Supplementary Figure S6), whereas VEGF-A (used as a positive 
control) induced BEC and HUVEC proliferation 1.5-2.0-fold.  
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Deletion of insulin receptor expression in blood vascular endothelial cells in vivo 
does not affect angiogenesis but attenuates tumor metastasis. 
Finally, we aimed to assess the role of endothelial INSR expression in tumor 
growth, metastasis and angiogenesis, using a syngenic murine BC model (MB49). 
Tumor cells were injected subcutaneously into mice with an endothelial cell–specific 
inactivation of the INSR gene (Tie2-Cre+ INSRfl/fl) and control littermates (Tie2-Cre-
INSRfl/fl; Figure 6A). In these mice, Tie2-promoter driven Cre expression lead to an 
efficient deletion of INSR (Figure 6B). 14 days after tumor inoculation, the tumor 
sizes and tumor weight in the two groups were similar (Figure 6C-D). However, we 
observed a tendency towards a reduced incidence of lymph node metastasis in 
endothelial INSR-deficient (Cre+) mice (Figure 6E). No difference in the incidence 
in neither liver nor lung metastasis was detectable (Figure 6F), but we noted a 
tendency for a reduced size of metastasis at these sites in Cre+ mice, based on 
bioluminescence measurements (Figure 6G). Furthermore, histologic analysis of the 
primary tumors revealed no obvious differences in the blood vessel density (Figure 
6H), and area, nor in the hypoxic (pimonidazole positive) area (Figure 6H-J), 
indicating that tumor angiogenesis is not dependent on INSR signaling in endothelial 
cells, but that endothelial INSR may be involved in the metastatic process. 
 
Discussion  
IBC is a dreadful disease, which, despite aggressive therapy such as complete 
cystectomy, has a high tendency to recur and a generally very poor prognosis. Our 
study reveals that high vascular INSR expression correlates with a much lower 
progression-free and overall survival in IBC. INSR may therefore represent a novel 
prognostic biomarker for this disease. Although associated with a much better 
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prognosis than IBC, NIBCs also have a high-risk to recur, and there are no 
biomarkers to predict recurrence [33]. Currently, patients have to undergo 
cystoscopies repeatedly [34], which are time-consuming, expensive and can cause 
damage to the urethra or lead to urinary tract infection [35]. Also in this case, high 
INSR expression on the vasculature of NIBC was associated with a tendency for more 
rapid recurrence of the tumor. Therefore, assessing INSR expression in tumor 
biopsies could contribute to a more secure prediction of recurrence in NIBC. Due to 
the limited sample size of our cohort, we were not able to reliably calculate whether 
vascular INSR was an independent predictor in a multivariate analysis. Therefore, 
additional studies using larger patient cohorts are warranted. Interestingly, in 
published expression datasets for IBC (TCGA, [14]) we found increased expression 
of INSR in the papillary-like Luminal Cluster I compared to other identified clusters. 
This cluster also showed upregulation of endocan and downregulation of 
thrombospondin 1, suggesting that this cluster could be angiogenic. Furthermore, 
increased expression of INSR was found in IBC of papillary histology versus IBC of 
non-papillary histology. 
Regarding the mechanism behind INSR upregulation, our data suggest that 
INSR is directly triggered by hypoxia, which was frequently present in BC tissue, via 
activation of HIF1A. INSR expression correlated with the expression of GLUT1, a 
hypoxia responsive gene, in BC tissue, and GLUT1 expression in isolated tBEC 
suggested that the tumor-associated endothelium might be hypoxic itself. We also 
identified a putative enhancer of INSR which interacts with HIF1A and which may be 
responsible for the hypoxia-inducible INSR upregulation in BECs. Interestingly, we 
could not detect an upregulation of INSR in BC cells by immunohistochemical 
staining in spite of the presence of hypoxic (GLUT1-positive) regions in BC tissue, 
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indicating that HIF1A induces INSR transcription only in ECs, possibly due to an 
inactivation of the responsible enhancer region in BC cells.  
On the other hand, hypoxia led to increased production of IGF-2 by cultured 
BECs and BC cells. Re-analysis of several large transcriptional profiling studies 
showed that IGF-2 is upregulated in human BCs compared to normal bladder tissue 
and that high IGF-2 expression levels were associated with reduced overall survival 
of patients with IBC, even though the difference was not as pronounced as for high 
INSR expression. The finding of elevated IGF-2 production by the tumors and 
preferential upregulation of INSR-A expression on the tBECs strongly suggests the 
activation of a paracrine cross-talk between tumor cells and tBECs, which correlates 
with poor prognosis.  
It is interesting to note that several epidemiological studies have revealed that 
patients with diabetes mellitus type 2 have an increased incidence and mortality of BC 
[36] and a higher incidence of IBC [37]. In patients with non-muscle IBC (pTa, pT1), 
diabetes mellitus type 2 was reported to be an independent risk factor for recurrence 
and to correlate with more aggressive features of the cancer [38,39]. It can be 
speculated that in diabetes mellitus type 2, INSR expression levels on blood vessels 
are elevated to compensate for reduced insulin signaling, and that this leads to the 
worsened prognosis for BC in diabetes mellitus type 2 patients by the mechanisms 
shown in the present study. Interestingly, in our study only in the samples with INSR 
positive staining we could also find patients with diabetes mellitus.  
Despite the prognostic value of INSR and IGF-2 expression in BC, it is not 
entirely clear what the functional consequence of this signaling pathway are, and 
whether it could serve as a therapeutic target as well. Our in vitro data suggest that 
IGF-2 binding to endothelial cell expressed INSR stimulates endothelial migration, 
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indicating a pro-angiogenic activity. On the other hand, we found no effect of IGF-2 
on endothelial proliferation in vitro, and the blood vessel density in tumors of mice 
lacking INSR expression in endothelial cells was not altered. Therefore, IGF-2/INSR 
signaling may promote angiogenesis, but is clearly not required in vivo, at least as 
long as other angiogenic pathways in the tumor microenvironment remain intact. It is 
tempting to speculate that role of the IGF-2/INSR pathway in tumor angiogenesis is 
redundant with other pathways, such as the VEGF-A/VEGFR-2 pathway, and may 
compensate in the case of VEGF-A targeted therapy, which may explain the 
resistance of BC against this therapy. Indeed, our in vitro data shows that IGF-2 can 
stimulate endothelial migration even in the presence of VEGFR-2 blocking 
antibodies. 
On the other hand, our findings that INSR deletion in endothelial cells slightly 
reduced tumor metastasis in tumor draining and non-draining lymph nodes, as well as 
in the lung and the liver, opens the possibility that INSR signaling may control other 
endothelial parameters, e.g. endothelial permeability, which may facilitate the 
systemic spread of cancer cells via the blood circulation. It is of interest that - in the 
TCGA expression dataset of IBC [14] - cancers with lymphovascular invasion and 
IBCs that metastasized had significantly increased levels of INSR. 
From a pharmacological point of view, specific targeting of INSR-A, in 
contrast to INSR-B which is involved in the metabolic effects of insulin in muscle, 
adipose tissue and liver [40], could well become a novel and safe strategy in BC 
treatment as it avoids metabolic adverse effects. Another approach could be to target 
IGF-2. A dual IGF-1/-2 neutralizing antibody was indeed successful in preclinical 
tumor mouse studies [41]. Currently, this antibody is in clinical trials for metastatic 
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breast cancer [42]. Based on our results presented here, IBC may represent another 
indication for this drug in the future.  
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Figure 1. High expression levels of INSR on blood vessels of bladder cancer are 
associated with shorter progression-free and overall survival of patients. 
 (A) Blood vessel endothelial cells (BEC) were isolated from frozen sections of 
invasive bladder cancers (tBEC) and adjacent normal bladder tissue (nBEC)  (n=5). 
Insulin receptor mRNA was quantified by RT-qPCR and normalized to the mean 
expression in nBEC. (B) Paraffin sections of bladder cancer and normal bladder tissue 
were stained for insulin receptor (upper lane, dark red) and counterstained with 
hematoxylin. To identify the blood vessels, von Willebrand factor (vWF) was 
detected on the same section by immunofluorescence staining (lower lane, red). 
Hoechst 33342 was used as nuclear counterstain. (C) A tissue microarray of 63 
invasive bladder cancers (pTa-CIS, pT1, pT2, pT3, pT4) was stained for INSR. The 
levels of expression on blood vessels (indicated by black arrows) were semi-
quantitatively assessed by grading the intensity of the staining as absent (0), weak 
(1+), or strong (2+). The Kaplan-Meier curves of progression-free (D) and overall 
survival (E) of the patients with strong insulin receptor expression (2+) and of those 
with weak or absent insulin receptor expression (1+, 0) were compared. (F) A tissue 
microarray of 90 non-invasive bladder cancers (pTa) was stained for INSR. Insulin 
receptor expression on blood vessels (indicated by black arrows) was semi-
quantitatively assessed by grading the intensity of the staining as absent (0), weak 
(1+), or strong (2+). (G) The Kaplan-Meier curves of recurrence-free survival of the 
patients with strong insulin receptor expression (2+) and those with weak or absent 
insulin receptor expression (1+, 0) were compared. Scale bars correspond to 100 μm. 
 
Figure 2. INSR expression by blood vascular endothelial cells is upregulated by 
hypoxia. 
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(A) HUVECs and BECs were subjected to hypoxia (1% O2) for 24 h. INSR mRNA 
expression was quantified by RT-qPCR and normalized to the mean expression by 
cells cultured under normoxic conditions (control). (B) INSR expression was 
quantified in primary human bladder cancer cell lines representing high (T24) or 
medium grade bladder cancer (HTB2 and HTB9), and differentiated urothelium 
(UROtsa), after 24 h of hypoxia  (1% O2). (C) A tissue microarray of 63 invasive 
bladder cancers (pTa-CIS, pT1, pT2, pT3, pT4) previously stained for INSR was 
stained for GLUT1. Representative examples of consecutive sections (upper panels: 
INSR; lower panels: GLUT1). Black arrows indicate blood vessels. Scale bars 
correspond to 100 μm. (D) Scoring of INSR staining for vessels and GLUT1 staining 
for tumors in the TMA of 63 invasive cancers. (E) As a measure for hypoxia in the 
tumor-associated blood vessels GLUT1 mRNA was measured by RT-qPCR in tBEC 
and nBEC isolated by LCM from invasive cancers of 5 patients with bladder cancer. 
Data are presented as mean ± SD. *P<0.05, **P<0.01. (F) Correlation of relative 
(delta Ct, comparison to the reference gene RPLP0) expression of INSR and GLUT1 
in tBEC and nBEC from 5 patients with bladder cancer. (G) A UCSC Genome 
Browser screenshot of the genomic region harboring the insulin receptor gene (INSR, 
chr19: 7,112,266 – 7,294,011), represented by the RefSeq gene model is shown. From 
top to bottom, the tracks show: DNase I hypersensitivity sites from 125 cell types 
investigated in the ENCODE project, ENCODE ChIP-Seq chromatin signal of 
H3K4me1, H3K4me3, and H3K27ac from HUVEC cultured under normoxic 
conditions, a ChIA-PET interaction between a putative enhancer region and the 
transcription start site (TSS) of INSR in HUVEC cultured under normoxic conditions 
(from Papantonis et al., [24]), CHIP-Seq peaks of H3K27ac in HUVEC cultured 
under normoxic and hypoxic conditions (from Inoue et al., [43]), a ChIP-Seq peak of 
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HIF1A in HUVEC cultured under hypoxic conditions and absence of this peak under 
normoxic conditions (from Mimura et al., [44]). The red rectangles highlight the 
putative enhancer region and the transcriptional start site (TSS) of insulin receptor. 
 
Figure 3. INSR isoform-A is the major isoform expressed in tumor-associated 
endothelial cells and in endothelial cells in vitro. 
The alternatively spliced isoforms of insulin receptor, INSR–A and INSR–B were 
quantified by RT-qPCR in BECs isolated from frozen sections of human invasive 
bladder cancer (n=5, tBEC) and adjacent normal bladder tissue (n=5, nBEC) (A), as 
well as in cultured BECs and HUVECs (B). Data are presented as mean fold-change ± 
SD. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 4. IGF-2 is upregulated by hypoxia and higher levels of IGF-2 are 
associated with shorter overall survival of patients with IBC.  
(A) Expression of IGF-2 by BEC subjected to hypoxia (1% O2) for 24 h was 
quantified by RT-qPCR and normalized to the mean expression by cells kept under 
normoxic conditions (control). (B) IGF-2 expression was quantified in primary human 
bladder cancer cell lines representing high (T24) or medium grade bladder cancer 
(HTB2 and HTB9), and differentiated urothelium (UROtsa), after 24 h of hypoxia  
(1% O2).  (C-E) IGF-2 expression in both invasive and non-invasive bladder cancers 
(IBC and NIBC) was compared to IGF-2 expression in normal bladder tissue (NB) 
and/or normal tissue adjacent to bladder cancers (NAB) using the publicly available 
datasets from Sanchez-Carbayo et al. ([26], C), Dyrskjot et al. ([27], D), and Lee at al. 
([28], E). (F-G) Kaplan-Meier curves of patient survival were compared between the 
IBCs expressing higher IGF-2 levels and those expressing lower levels in the study by 
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Lee et al. (F) and between the bladder cancers expressing higher and lower IGF-2 
levels from the TCGA (G). Data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001. Horizontal lines in (C-E) denote mean values. 
 
Figure 5. IGF-2 is potent activator of endothelial migration through INSR, 
independently of VEGFR-2 inhibition. 
Migration of BECs in response to increasing concentrations of (A) IGF-2 was 
assessed using a scratch closure assay. Significance testing was performed between 
control and treated samples. (B) Migration induced by VEGFA and / or IGF-2 was 
measured in presence of a VEGFR-2 blocking antibody or an isotype-matched 
irrelevant antibody. (C-E) Increasing concentrations of an INSR blocking antibody 
(IR Ab, C), IGF-1R inhibitor (PPP, D) and dual INSR and IGF1R inhibitor 
(GSK1838705, E) were used to assess the contribution of INSR and IGF-1R in IGR-2 
induced migration. Data from one representative experiment are presented as mean ± 
SD. *P<0.05, **P<0.01, ***P<0.001. 
  
Figure 6. Loss of insulin receptor expression on blood vascular endothelial cells 
in vivo attenuates bladder cancer metastasis.   
 (A) Schematic diagram of the transgenic mouse genomic constructs used to generate 
C57Bl6 mice lacking INSR on BECs (Tie2-Cre+ INSRfl/fl). (B) RT-qPCR 
quantification on the extent of exon 4 deletion from the INSR locus in FACS sorted 
endothelial cells from the ear dermis.  (C) The volume of MB49 tumors injected s.c. 
in control (Tie2-Cre- INSRfl/fl (Cre-); n=11) and in mice lacking INSR on blood 
vascular endothelial cells (Tie2-Cre+ INSRfl/fl (Cre+); n=13) was measured every 
second day. (D) Tumor weight was measured on the day of sacrifice. (E) Lymph 
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nodes (LN) from tumor-bearing Cre+ or Cre- mice were assessed for incidence of 
metastasis using bioluminescence imaging. (F) Lung and liver from tumor-bearing 
Cre+ or Cre- mice were assessed for incidence of metastasis using bioluminescence 
imaging. (G) Using the bioluminescence signal intensity, the extent of metastasis in 
Cre+ and Cre- mice was quantified. (H-I) MB49 tumor sections from Cre+ and Cre- 
mice were stained for MECA32 (mouse blood vascular endothelial cell marker) and 
number of vessels (H) and area covered by vessels (I) was assessed. (J) Tumor 
hypoxia was analyzed by staining for pimonidazole-protein adducts. Data are  
presented as mean ± SD. 
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Figure S1.  Insulin receptor is highly expressed on blood vessels in a variety of 
human solid tumors 
 
Figure S2. Insulin receptor is not expressed on blood vessels of healthy human 
tissues 
 
Figure S3. Insulin receptor expression is elevated in invasive bladder cancers with 
molecular profiles of the papillary-like luminal cluster I and in bladder cancers with 
papillary histology, and correlates with lymphatic invasion and metastasis 
 
Figure S4. GLUT1 is upregulated by hypoxia in endothelial cells in vitro while IGF-1 
is not 
 
Figure S5. Insulin receptor mediates the stimulation of human blood vascular 
endothelial cell migration by insulin while IGF-1R mediates the effects of IGF-1 
 
Figure S6. Insulin, IGF-1 and IGF-2 have no major effect on the proliferation of 
cultured blood vascular endothelial cells under normoxic or hypoxic conditions 
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Table S1.  Clinico-pathologic characteristics of the patients with invasive bladder 
cancer whose samples are contained in the TMA. Quantification of 
immunohistochemical staining for insulin receptor on blood vessels and GLUT1 on 
tumor cells in the TMA 
 
Table S2.  Clinico-pathologic characteristics of the patients with non-invasive bladder 
cancer whose samples are contained in the TMA. Quantification of 
immunohistochemical staining for insulin receptor on blood vessels in the TMA 
 
Table S3.  Sequences of PCR and RT-qPCR primers 
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Supplementary Table S1. Clinico-pathologic characteristics of the patients with invasive bladder cancer whose samples are contained in the TMA. 
Quantification of immunohistochemical staining for insulin receptor on blood vessels and GLUT1 on tumor cells in the TMA.
Variable Categorization n analyzable %
Total number of patients=66
Clinico-pathologic data:
Age at diagnosis (median, range) 63.35 (43-82)
<70 47 71.2
≥70 19 28.8
Sex
Female 16 24.2
Male 50 75.8
Tumor stage (WHO 1973)
Solitary CIS 1 1.5
pTa 2 3.0
pT1 9 13.6
pT2 18 27.3
pT3 27 40.9
pT4 9 13.6
Histologic grade (WHO 1973)
G2 5 7.6
G3 61 92.4
Adjacent carcinoma in situ
No 39 59.1
Yes 27 40.9
Venous invasion
No 54 81.8
Yes 12 18.2
Lymphatic invasion
No 48 72.7
Yes 18 27.3
Lymph node positive
No 40 60.6
Yes 26 39.4
Immunohistochemistry (IHC):
Insulin receptor
Absent, weak or medium expression 51 77.3
Strong expression 12 18.2
Few vessels observed 3 4.5
GLUT1	  (SLC2A1)
Absent or weak expression 30 47.6
Strong expression 33 52.4
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Supplementary Table S2. Clinico-pathologic characteristics of the patients with non-invasive bladder cancer whose samples are contained in the TMA. 
Quantification of immunohistochemical staining for insulin receptor on blood vessels  in the TMA.
Variable Categorization n analyzable %
Total number of patients=90
Clinico-pathologic data:
Age at diagnosis (median, range) 68.5 (32-88)
<70 49 54.4
≥70 41 45.6
Sex
Female 20 22.2
Male 70 77.8
Tumor stage (WHO 1973)
pTa 90 100.0
Histologic grade (WHO 1973)
G1 39 43.3
G2 48 53.3
G3 3 3.3
Histologic grade (WHO 2004)
Low grade 72 80.0
High grade 18 20.0
Adjacent carcinoma in situ
No 89 98.9
Yes 1 1.1
Multiplicity
Solitary 74 82.2
Multifocal 16 17.8
Growth pattern
papillary 89 98.9
solid 1 1.1
Immunohistochemistry (IHC):
Insulin receptor
No or weak expression 37 41.1
Strong expression 53 58.9
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Supplementary Table S3. Sequences of PCR and RT-qPCR primers
Gene symbol species purpose sequence 5'-3'
SLC2A1 (GLUT1) human RT-qPCR GGCCAAGAGTGTGCTAAAGAA (forward)
ACAGCGTTGATGCCAGACAG (reverse)
IGF1 human RT-qPCR GCAATGGGAAAAATCAGCAG (forward)
GAGGAGGACATGGTGTGCA (reverse)
IGF2 human RT-qPCR CCGTGCTTCCGGACAACTT (forward)
CTGCTTCCAGGTGTCATATTGG (reverse)
INSR human RT-qPCR AGGAGCCCAATGGTCTGA (forward)
GAGACGCAGAGATGCAGC (reverse)
INSR-A human RT-qPCR TGGTTTTCGTCCCCAGGC (forward)
CCACCGTCACATTCCCAAC (reverse)
INSR-B human RT-qPCR GTGCCGAGGACCCTAGGCC (forward)
CCACCGTCACATTCCCAAC (reverse)
INSR mouse genomic PCR (detecting flox sequence) CTCAACTGAGATCCCCCTCA (forward)
CTGAATAGCTGAGACCACAG (reverse)
INSR mouse RT-qPCR for detecting deletion of exon 4 ATAAGTGCATCCCCGAGTGC (forward)
                  CTGAATAGCTGAGACCACAG (reverse)
RPLP0 human RT-qPCR reference gene CAGATTGGCTACCCAACTGTT (forward)
GGGAAGGTGTAATCCGTCTCC (reverse)
RPLP0 mouse RT-qPCR reference gene AGATTCGGGATATGCTGTTGGC (forward)
TCGGGTCCTAGACCAGTGTTC (reverse)
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